Skip to main content
SpringerLink
Log in

Adamantiades-Behçet’s disease

  • Chapter
European Handbook of Dermatological Treatments

Abstract

Adamantiades-Behçet’s disease is a relapsing multisystemic inflammatory disorder of unknown aetiology, classified as systemic vasculitis and characterized by recurrent oral and genital ulcers, cutaneous lesions and uveitis. It exhibits a worldwide occurrence with varying prevalence, presenting endemically in the eastern Mediterranean and in Middle and Far Eastern countries and is rare among inhabitants of north European countries, in central and southern Africa, in the Americas and in Australia. A prevalence of 80–370 patients per 100 000 inhabitants has been reported in Turkey, 2–30 patients per 100000 inhabitants in the rest of the Asian continent (Japan 14–30/100 000; Iran 17/ 100 000; China 14/100 000) and 0.1–2.5 patients per 100 000 inhabitants in Europe and the USA.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Further reading

  • Alpsoy E, Er H, Durusoy C, Yilmaz E. The use of sucralfate suspension in the treatment of oral and genital ulceration of Behçet’s disease. Arch Dermatol 1999; 135: 529–32.

    Article  PubMed  CAS  Google Scholar 

  • Avci O, Gürler N, Günes AT. Efficacy of cyclosporine on mucocutaneous manifestations of Behçet’s disease. J Am Acad Dermatol 1997; 36: 796–7.

    Article  PubMed  CAS  Google Scholar 

  • Bang D. Treatment of Behcet’s disease. Yonsei Med 1997; 38: 401–10.

    CAS  Google Scholar 

  • Binnie WH, Curro FA, Khandwala A, Van Inwegan RG. Amlexanox oral paste. A novel treatment that accelerates the healing of aphthous ulcers. Compend Contin Educ Dent 1997; 18: 1116–24.

    PubMed  CAS  Google Scholar 

  • Calderon P, Anzilotti M, Phelps R. Thalidomide in dermatology. New indications for an old drug. Int J Dermatol 1997; 36: 881–7.

    Article  PubMed  CAS  Google Scholar 

  • Calgüneri M, Kiraz S, Ertenli I, Benekli M, Karaarslan Y, Çelik I. The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behcet’s disease. A randomized clinical trial. Arthritis Rheum 1996; 39: 2062–5.

    Article  PubMed  Google Scholar 

  • Chahine L, Sempson N, Wagoner C. The effect of sodium lauryl sulfate on recurrent aphthous ulcers: a clinical study. Compend Contin Educ Dent 1997; 18: 1238–40.

    PubMed  CAS  Google Scholar 

  • Chandrasekhar J, Liem AA, Cox NH, Paterson AW. Oxypentifylline in the management of recurrent aphthous oral ulcers: an open clinical trial. Oral Surg Oral Med Oral Pathol Oral Radio! Endod 1999; 87: 564–7.

    Article  CAS  Google Scholar 

  • de Wazières B, Gil H, Magy N, Berthier S. Vuitton DA, Dupond JL. Traitement de L’aphthose récurrente par thalidomide à faible dose. Etude pilote chez 17 patients. Rev Méd Int 1999; 20: 567–70.

    Article  Google Scholar 

  • Ehrlich GE. Behçet’s disease: an update. Comp Ther 1999; 25: 216–20.

    Article  CAS  Google Scholar 

  • Fridh G, Koch G. Effect of a mouth rinse containing amyloglucosidase and glucose oxidase on recurrent aphthous ulcers in children and adolescents. Swed Dent J 1999; 23: 49–57.

    PubMed  CAS  Google Scholar 

  • Gardner-Medwin JMM, Smith NJ, Powell RJ. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet’s disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 1994; 53: 828–32.

    Article  PubMed  CAS  Google Scholar 

  • Ghate JV, Jorizzo JL. Behçet’s disease and complex aphthosis. J Am Acad Dermatol 1999; 40: 1–18.

    Article  PubMed  CAS  Google Scholar 

  • Hamuryudan V, Mat C, Saip S et al Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 443–50.

    PubMed  CAS  Google Scholar 

  • Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet’s disease: a case report. Gastroenterology 2001; 120: 995–9.

    Article  PubMed  CAS  Google Scholar 

  • Healy CM, Paterson M, Joyston-Bechal S, Williams DM, Thornhill MH. The effect of a sodium lauryl sulfate-free dentifrice on patients with recurrent oral ulceration. Oral Dis 1999; 5: 39–43.

    Article  PubMed  CAS  Google Scholar 

  • Hornstein OP. Aphthen und aphthoide Läsionen der Mundschleimhaut. Hals-Nasen-Ohren-Arzt 1998; 46: 102–11.

    CAS  Google Scholar 

  • International Study Group for Behçet’s disease. Criteria for diagnosis of Behçet’s disease. Lancet 1990; 335: 1078–80.

    Google Scholar 

  • Jorizzo JL, Schmalstieg FC, Solomon AR Jr et al Thalidomide effects in Behçet’s syndrome and pustular vasculitis. Arch Intern Med 1986; 146: 878–81.

    Article  PubMed  CAS  Google Scholar 

  • Jorizzo JL, White WL, Wise CM, Zanolli MD, Sherertz EF. Low-dose weekly methotrexate for unusual neutrophilic vascular reactions. cutaneous polyarteriitis nodosa and Behçet’s disease. J Am Acad Dermatol 1991; 24: 973–8.

    Article  PubMed  CAS  Google Scholar 

  • Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behçet’s disease. Sem Arthritis Rheum 1998; 27: 197–217.

    Article  CAS  Google Scholar 

  • Kotake S, Higashi K, Yoshikawa K, Sasamoto Y, Okamoto T, Matsuda H. Central nervous system symptoms in patients with Behcet disease receiving cyclosporine therapy. Ophthalmology 1999; 106: 586–9.

    Article  PubMed  CAS  Google Scholar 

  • Kötter I, Eckstein AK, Stübiger N, Zierhut M. Treatment of ocular symptoms of Behçet’s disease with interferon n2: a pilot study. Br J Ophthalmol 1998; 82: 488–94.

    Article  PubMed  Google Scholar 

  • Mochizuki M. Immunotherapy for Behcet’s disease. Int Rev Immunol 1997; 14: 49–66.

    Article  PubMed  CAS  Google Scholar 

  • Oyama N, Inoue M, Matsui T, Nuhei Y, Nishibu A, Kaneko F. Minocycline effects on the clinical symptoms in correlation with cytokines produced by peripheral blood mononuclear cells stimulated with streptococcal antigens in Behçet’s disease. In: Hamza M, ed. Behçet’s Disease. Tunis: Publications Adhoua, 1997: 481–6.

    Google Scholar 

  • Özyazgan Y, Hizli N, Mat C et al Azathioprine in Behcet’s syndrome. effects on longterm prognosis. Arthritis Rheum 1997; 40: 769–74.

    Article  PubMed  Google Scholar 

  • Rogers RS III. Recurrent aphthous stomatitis in the diagnosis of Behçet’s disease. Yonsei Med J 1997; 38: 370–9.

    PubMed  Google Scholar 

  • Sakane T, Takeno M. Novel approaches to Behcet’s disease. Expert Opin Invest Drugs 2000; 9: 1993–2005.

    Article  CAS  Google Scholar 

  • Sakane T, Takeno M, Suzuki N, Inaba G. Behçet’s disease. NEngl JMed 1999; 341: 1284–91.

    Article  CAS  Google Scholar 

  • Samangooci SH, Mehryar M, Hakim SM, Safamanesk S. Clinical trial of sulfasalazine for treatment of uveitis Behçet’s disease. In: Hamza M, ed. Behçet’s Disease. Tunis: Publications Adhoua, 1997: 466–70.

    Google Scholar 

  • Saxen MA, Ambrosius WT, Rehemtula al-KF Russell AL, Eckert GJ. Sustained relief of oral aphthous ulcer pain from topical diclofenac in hyaluronan: a randomized, double-blind clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997; 84: 356–61.

    Article  PubMed  CAS  Google Scholar 

  • Stadler R, Bratzke B, Orfanos CE. Therapeutischer Einsatz von alpha-Interferon bei metastasierendem malignen Melanom, disseminiertem Kaposi-Sarkom and schwerem Morbus Behçet. Hautarzt 1987; 38: 453–60.

    PubMed  CAS  Google Scholar 

  • Tanaka C, Matsuda T, Yukinari Y et al The beneficial effect of rebamipide on recurrent aphthous ulcers in Behçet’s disease. In: Hamza M, ed. Behçet’s Disease. Tunis: Publications Adhoua, 1997: 477–80.

    Google Scholar 

  • Treudler R, Orfanos CE, Zouboulis CC. Twenty eight cases of juvenile-onset AdamantiadesBehçet’s disease in Germany. Dermatology 1999; 199: 15–19.

    Article  PubMed  CAS  Google Scholar 

  • Yasui K, Ohta K, Kobayashi M, Aizawa T, Komiyama A. Successful treatment of Behçet’s disease with pentoxifylline. Ann Intern Med 1996; 124: 891–3.

    PubMed  CAS  Google Scholar 

  • Yazici H. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 443–50.

    PubMed  Google Scholar 

  • Yazici H, Barnes CG. Practical treatment recommendations for pharmacotherapy of Behçet’s syndrome. Drugs 1991; 42: 796–804.

    Article  PubMed  CAS  Google Scholar 

  • Yazici H, Yurdakul S, Hamuryudan V. The management of Behçet’s syndrome: how are we doing? Clin Exp Rheumato 1999; 17: 145–7.

    CAS  Google Scholar 

  • Zouboulis CC. Morbus Adamantiades-Behçet: Kli-nische und experimentelle Befunde von 53 Patienten aus dem Berliner Raum. Habilitationsschrift. Berlin: Freie Universität Berlin, 1995.

    Google Scholar 

  • Zouboulis CC. Morbus Adamantiades-Behçet in Deutschland: Historischer Rückblick und aktueller Kenntnisstand. Z Hautkr 1996; 71: 491–501.

    Google Scholar 

  • Zouboulis CC. Adamantiades-Behçet’s disease. In: Katsambas AD, Lotti T, eds. European Handbook of Dermatological Treatments. Berlin: Springer: 1999, 21–30.

    Google Scholar 

  • Zouboulis CC. Epidemiology of AdamantiadesBehçet’s disease. Ann Med Int 1999; 150: 488–98.

    CAS  Google Scholar 

  • Zouboulis CC, Katsantonis J, Ketteler R et al Adamantiades-Behçet’s disease. Interleukin-8 is increased in serum of patients with active oral and neurological manifestations and is secreted by small vessel endothelial cells. Arch Dermatol Res 2000; 292: 279–84.

    Article  PubMed  CAS  Google Scholar 

  • Zouboulis CC, Kötter I, Djawari D et al Epidemiological features of Adamantiades-Behçet’s disease in Germany and in Europe. Yonsei Med J 1997; 38: 411–22.

    PubMed  CAS  Google Scholar 

  • Zouboulis CC, Orfanos CE. Treatment of Adamantiades-Behçet’s disease with systemic interferon alfa. Arch Dennatol 1998; 134: 1010–16.

    Article  CAS  Google Scholar 

  • Zouboulis CC, Treudler R, Orfanos CE. Morbus Adamantiades-Behçet. therapeutischer Einsatz von systemischen rekombinantem Interferonalpha-2a. Hautarzt 1993; 44: 440–5.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Ch. C. Zouboulis
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. ‘A. Sygros’ Hospital, Department of Dermatology, University of Athens, 5, I. Dragoumi Street, 161 21, Athens, Greece

    Andreas D. Katsambas

  2. University Unit Allergology Professional and Environmental Dermatology, University of Florence, Via Alfani 37, 50 121, Florence, Italy

    Torello M. Lotti

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Zouboulis, C.C. (2003). Adamantiades-Behçet’s disease. In: Katsambas, A.D., Lotti, T.M. (eds) European Handbook of Dermatological Treatments. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-07131-1_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-07131-1_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-05657-4

  • Online ISBN: 978-3-662-07131-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation